Changes in the cost-effectiveness of pneumococcal vaccination and of programs to increase its uptake in U.S. older adults.
Angela R WateskaMary Patricia NowalkShoroq M AltawalbehChyongchiou J LinLee H HarrisonWilliam SchaffnerRichard K ZimmermanKenneth J SmithPublished in: Journal of the American Geriatrics Society (2024)
Current U.S. pneumococcal vaccination recommendations for older adults were unlikely to be economically reasonable with or without programs to increase vaccine uptake. Alternatives to current pneumococcal vaccines that include pneumococcal serotypes associated with adult disease should be considered.
Keyphrases